These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 15725808)

  • 1. Immunohistochemistry can help distinguish metastatic pancreatic adenocarcinomas from bile duct adenomas and hamartomas of the liver.
    Hornick JL; Lauwers GY; Odze RD
    Am J Surg Pathol; 2005 Mar; 29(3):381-9. PubMed ID: 15725808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Albumin expression distinguishes bile duct adenomas from metastatic adenocarcinoma.
    Moy AP; Arora K; Deshpande V
    Histopathology; 2016 Sep; 69(3):423-30. PubMed ID: 26841202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRAF V600E mutational status in bile duct adenomas and hamartomas.
    Pujals A; Bioulac-Sage P; Castain C; Charpy C; Zafrani ES; Calderaro J
    Histopathology; 2015 Oct; 67(4):562-7. PubMed ID: 25704541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential diagnosis of malignant epithelial tumours in the liver: an immunohistochemical study on liver biopsy material.
    Al-Muhannadi N; Ansari N; Brahmi U; Satir AA
    Ann Hepatol; 2011; 10(4):508-15. PubMed ID: 21911893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Panels of immunohistochemical markers help determine primary sites of metastatic adenocarcinoma.
    Park SY; Kim BH; Kim JH; Lee S; Kang GH
    Arch Pathol Lab Med; 2007 Oct; 131(10):1561-7. PubMed ID: 17922593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reevaluation and identification of the best immunohistochemical panel (pVHL, Maspin, S100P, IMP-3) for ductal adenocarcinoma of the pancreas.
    Liu H; Shi J; Anandan V; Wang HL; Diehl D; Blansfield J; Gerhard G; Lin F
    Arch Pathol Lab Med; 2012 Jun; 136(6):601-9. PubMed ID: 22646265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. WT1, monoclonal CEA, TTF1, and CA125 antibodies in the differential diagnosis of lung, breast, and ovarian adenocarcinomas in serous effusions.
    Zhu W; Michael CW
    Diagn Cytopathol; 2007 Jun; 35(6):370-5. PubMed ID: 17497661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dpc-4 protein is expressed in virtually all human intraductal papillary mucinous neoplasms of the pancreas: comparison with conventional ductal adenocarcinomas.
    Iacobuzio-Donahue CA; Klimstra DS; Adsay NV; Wilentz RE; Argani P; Sohn TA; Yeo CJ; Cameron JL; Kern SE; Hruban RH
    Am J Pathol; 2000 Sep; 157(3):755-61. PubMed ID: 10980115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of Dpc4 expression in colonic adenocarcinomas correlates with the presence of metastatic disease.
    Maitra A; Molberg K; Albores-Saavedra J; Lindberg G
    Am J Pathol; 2000 Oct; 157(4):1105-11. PubMed ID: 11021814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of thyroid transcription factor 1, PE-10, and cytokeratins 7 and 20 in discriminating between primary lung carcinomas and metastatic lesions in fine-needle aspiration biopsy specimens.
    Chhieng DC; Cangiarella JF; Zakowski MF; Goswami S; Cohen JM; Yee HT
    Cancer; 2001 Oct; 93(5):330-6. PubMed ID: 11668468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CK7, CK20, CDX2 and MUC2 Immunohistochemical staining used to distinguish metastatic colorectal carcinoma involving ovary from primary ovarian mucinous adenocarcinoma.
    Shin JH; Bae JH; Lee A; Jung CK; Yim HW; Park JS; Lee KY
    Jpn J Clin Oncol; 2010 Mar; 40(3):208-13. PubMed ID: 19926591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical labeling for dpc4 mirrors genetic status in pancreatic adenocarcinomas : a new marker of DPC4 inactivation.
    Wilentz RE; Su GH; Dai JL; Sparks AB; Argani P; Sohn TA; Yeo CJ; Kern SE; Hruban RH
    Am J Pathol; 2000 Jan; 156(1):37-43. PubMed ID: 10623651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intestinal-type cervical adenocarcinoma in situ and adenocarcinoma exhibit a partial enteric immunophenotype with consistent expression of CDX2.
    McCluggage WG; Shah R; Connolly LE; McBride HA
    Int J Gynecol Pathol; 2008 Jan; 27(1):92-100. PubMed ID: 18156982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utility of DNA flow cytometry in distinguishing between malignant and benign intrahepatic biliary lesions.
    Wen KW; Rabinovitch PS; Wang D; Mattis AN; Ferrell LD; Choi WT
    Virchows Arch; 2020 Oct; 477(4):527-534. PubMed ID: 32296928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The value of cytokeratins 20 and 7 in discriminating metastatic adenocarcinomas from pleural mesotheliomas.
    Tot T
    Cancer; 2001 Nov; 92(10):2727-32. PubMed ID: 11745209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of novel markers of pancreatic ductal adenocarcinoma in pancreatic nonductal neoplasms: additional evidence of different genetic pathways.
    Cao D; Maitra A; Saavedra JA; Klimstra DS; Adsay NV; Hruban RH
    Mod Pathol; 2005 Jun; 18(6):752-61. PubMed ID: 15696124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis.
    Hassan R; Laszik ZG; Lerner M; Raffeld M; Postier R; Brackett D
    Am J Clin Pathol; 2005 Dec; 124(6):838-45. PubMed ID: 16416732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of mesothelin, fascin, and prostate stem cell antigen in primary ovarian mucinous tumors and their utility in differentiating primary ovarian mucinous tumors from metastatic pancreatic mucinous carcinomas in the ovary.
    Cao D; Ji H; Ronnett BM
    Int J Gynecol Pathol; 2005 Jan; 24(1):67-72. PubMed ID: 15626919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Use of thyroid transcription factor-1, surfacfant protein-B, cytokeratin 7 and cytokeratin 20 in discrimination between primary and metastatic adenocarcinoma of lung].
    Zou SM; Lin DM; Lü N; Liu XY; Wen P; Liu FS
    Zhonghua Yi Xue Za Zhi; 2003 Aug; 83(15):1350-2. PubMed ID: 12930693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HepPar1, MOC-31, pCEA, mCEA and CD10 for distinguishing hepatocellular carcinoma vs. metastatic adenocarcinoma in liver fine needle aspirates.
    Wang L; Vuolo M; Suhrland MJ; Schlesinger K
    Acta Cytol; 2006; 50(3):257-62. PubMed ID: 16780018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.